Načítá se...
Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives
Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. Despite substantial in vitro cytotoxicity, response rates in early clinical trials with 4-HPR have been less than anticipated, likely due to the low bioavailability of the initial oral capsule formulation....
Uloženo v:
| Vydáno v: | Exp Biol Med (Maywood) |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5478002/ https://ncbi.nlm.nih.gov/pubmed/28429653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1535370217706952 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|